|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Expression of KDR (one of the VEGF receptors) mRNA in tumor exceeded that in normal tissues.
|
11679938 |
2001 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Inhibition of ALK1 signaling with dalantercept combined with VEGFR TKI leads to tumor stasis in renal cell carcinoma.
|
27248821 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These novel findings suggest that targeting the release of VEGF from tumor epithelial cells as well as blocking interactions between VEGF and VEGFR-2 on both endothelial and tumor epithelial cells may facilitate the development of new antiangiogenic therapies for progestin-dependent breast tumors.
|
15845615 |
2005 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Rising levels of markers of tumour burden (CK18) and potential resistance (VEGFR2) are associated with worse outcomes and warrant validation.
|
29925934 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Self-assembling nanoparticles with siRNA were constructed with polyethyleneimine (PEI) that is PEGylated with an Arg-Gly-Asp (RGD) peptide ligand attached at the distal end of the polyethylene glycol (PEG), as a means to target tumor neovasculature expressing integrins and used to deliver siRNA inhibiting vascular endothelial growth factor receptor-2 (VEGF R2) expression and thereby tumor angiogenesis.
|
15520458 |
2004 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In addition, microvascular endothelial cells strongly expressed mRNA of the VPF/VEGF receptors flt-1 and KDR and immunostained for VPF/VEGF protein in the majority of malignant and borderline tumors examined.
|
8667614 |
1996 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Among them, vascular endothelial growth factor receptor 2 (VEGFR2) inhibitors exerts potent antiangiogenic activity in tumor therapy.
|
28194552 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
A VEGFR inhibitor which preferentially suppressed tumor growth in NK cell-depleted mice was dependent on neutrophils.
|
29362222 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
After colitis induction, VEGFR2(ΔIEC) mice developed significantly fewer tumors than control mice.
|
25797700 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
<b>17</b>, a potent dual VEGFR3 and VEGFR2 inhibitor, effectively suppresses both lymphangiogenesis and angiogenesis in a 3D-microfluidic tumor lymphangiogenesis assay and in vivo corneal assay while SAR131675 blocks only lymphangiogenesis.
|
31513411 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The aim of this study was the evaluation of serum levels of osteopontin (OPN) and tumor endogenous angiogenic factors such as vascular-endothelial growth factor (VEGF), vascular-endothelial growth factor receptor 2 (VEGF R2), endostatin, angiostatin and thrombospondin 1, in prostate cancer (PC) patients.
|
30178447 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Co-administration delayed the tumour growth than mono-therapy in the xenograft model and had better effect on inhibiting the activation of EGFR and VEGFR2 and expression of CD31 (an angiogenesis marker) and vascular endothelial growth factor A (an important pro-angiogenesis factor in the tumour microenvironment).
|
28822888 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Cohorts of these tumor-bearing mice treated with Ad Flk1-Fc demonstrated significantly longer survival and decreased liver replacement with tumor at the time of death, relative to animals treated with Ad Fc.
|
12464871 |
2002 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
After being labeled with (64)Cu, PET imaging revealed specific and prominent uptake of (64)Cu-NOTA-RamAb in VEGFR-2-positive HCC4006 tumors (9.4 ± 0.5 percentage injected dose per gram at 48 h after injection; n = 4) and significantly lower uptake in VEGFR-2-negative A549 tumors (4.3 ± 0.2 percentage injected dose per gram at 48 h after injection; n = 3).
|
26541778 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
GW654652, an indazolylpyrimidine, is a VEGFRs tyrosine kinase inhibitor that dramatically reduces both angiogenesis and tumor cell growth in this model, as demonstrated using both in vitro and in vivo assays.
|
15592523 |
2005 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
A new enhanced Semliki Forest virus (SFV) expression vector is now available and this is particularly effective when used in combination with pro-inflammatory cytokines such as IL-12 or anti-angiogenic treatment based on the induction of autoimmunity to tumor endothelial cell antigen (vascular endothelial growth factor receptor 2).
|
18221060 |
2007 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Sunitinib (40 mg/kg, once daily), a receptor tyrosine kinase inhibitor of VEGFR2 and other growth factor receptors, also caused significant loss of tumor blood vessels in RCC models but had weaker effects than DC101 on pericytes and lymphatic vessels.
|
21245940 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Compared with radiotherapy alone, ES combined with radiotherapy can reduce brain edema in NSCLC patients with BM and obtain better short-term response rate in tumors with positive VEGFR2 or positive KDR gene, but does not improve the overall survival.
|
24193868 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
A cyclic peptide reproducing the α1 helix of VEGF-B binds to VEGFR-1 and VEGFR-2 and inhibits angiogenesis and tumor growth.
|
30700502 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Somatic mutations in genes encoding catenin beta 1 and vascular endothelial growth factor receptor 2 were identified in the patient's tumor sample compared to the normal tissue.
|
28915721 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Forced HGF expression in cancer cells reduced tumor sensitivity to VEGFR TKIs and produced tumors with tortuous blood vessels.
|
28559461 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The depression of VEGFR2 activity on T cells can significantly reduce the infiltration of Tregs into the tumor tissue.
|
28919780 |
2017 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The number of cells undergoing apoptosis was significantly increased in the KDR/Flk-1-ASO-treated tumors.
|
11857038 |
2002 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Chitosan sulfate inhibits angiogenesis via blocking the VEGF/VEGFR2 pathway and suppresses tumor growth in vivo.
|
30694269 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Tumors treated simultaneously with apatinib and cisplatin exhibited significantly-increased inhibition of tumor growth, prolonged survival time, decreased expression of VEGFR-2, reduced microvascular density, and frequency of apoptosis over standalone and sequential administration therapy.
|
28881773 |
2017 |